Biocon's Syngene in silent period but lays plans for API plant in India

By Dan Stanton contact

- Last updated on GMT

Syngene is buying 40 acres of land in Mangalore SEZ, India
Syngene is buying 40 acres of land in Mangalore SEZ, India

Related tags: Special economic zone

Biocon subsidiary Syngene says it intends to build a commercial manufacturing plant for APIs and intermediates in Mangalore, India.

Syngene International is a subsidiary of drugmaker Biocon and offers contract development and manufacturing services to both customers in its home country India, and international biopharma firms.

In a filing with the Bombay Stock Exchange (BSE), the firm announced it is “in the process of acquiring approximately 40 acres of land on leasehold basis in the multi-product Special Economic Zone [SEZ],” ​with the intention of “setting up commercial scale facilities for manufacture of novel Active Pharmaceutical Ingredients (APIs), Advanced Intermediates and Agro Chemicals for Syngene’s clients.”

As well as small molecule APIs, the CDMO produces biologics for its clients and is one of just a handful of Indian drugmakers​ which produce such products for Western biopharma companies. The firm also offers development services and last year announced a five-year extension of its collaboration with Bristol-Myers Squibb​.

The planned facility is located in Mangalore, Karnataka on the West coast of India. The announcement comes on the back of Biocon plans to build a biomanufacturing facility​ on the opposite side of India, at Pharma-City SEZ in Vizag, Andhra Pradesh.

SEZs offer businesses a number of incentives. The Mangalore site offers exemptions from industrial licensing norms including excise duty, purchase, service and sales tax.

IPO plans

This publication contacted parent company Biocon for more information, but spokesperson Seema Ahuja said the firm is in a silent period and cannot offer additional information.

Biocon is looking to list Syngene – India’s largest and Asia’s second-largest research services company – by the end of fiscal year 2015 and said in January it was hoping to sell up to 15% of its stake in the firm through an IPO.

In related news, Syngene’s Director, Peter Bains, has been appointed CEO of the subsidiary.

Related news

Show more

Related products

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more